...
首页> 外文期刊>BMC Infectious Diseases >Retesting and repeat positivity following diagnosis of Chlamydia trachomatis and Neisseria gonorrhoea in New Zealand: a retrospective cohort study
【24h】

Retesting and repeat positivity following diagnosis of Chlamydia trachomatis and Neisseria gonorrhoea in New Zealand: a retrospective cohort study

机译:在新西兰诊断出沙眼衣原体和淋病奈瑟菌后复检并重复阳性:一项回顾性队列研究

获取原文

摘要

Background Testing for reinfection at 3 to 6?months following treatment for Chlamydia Trachomatis or Neisseria gonorrhoea is recommended in best practice sexual health management guidelines. This study aimed to describe rates of retesting and repeat positivity following diagnosis of chlamydia or gonorrhoea in a defined geographic region of New Zealand. Methods Retrospective cohort study in Wellington, New Zealand involving analysis of laboratory data for chlamydia and gonorrhoea tests performed in primary care and sexual health clinics (July 2012–July 2015). Outcome measures: rate of retesting and rate of repeat positivity 6?weeks to 6?months after a positive result (index event). Kaplan-Meier curves were used to plot time from first index event to retest. Logistic regression modelling was used to determine the odds of retesting and repeat positivity between 6?weeks and 6?months of follow-up, adjusting for potential confounders (age, gender, ethnicity and socioeconomic deprivation). Results Overall 29.4% (1919/6530) of the cohort was retested between 6?weeks and 6?months, with 18% (347/1919) of those retested returning positive results. Lower odds of retesting were observed for males (OR 0.4, 95% CI 0.34–0.48), and individuals of NZ Maori (OR 0.72, 0.61–0.85) and Pacific ethnicities (OR 0.49, 0.39–0.62, reference European). Factors associated with higher odds of repeat positivity on retesting included male gender (OR 2.0, 1.14–2.82), age 15–19?years (OR 1.78, 1.32–2.41, reference 20–24?years), chlamydia/gonorrhoea co-infection (OR 2.39, 1.32–4.35, reference chlamydia only), Maori (OR 1.6, 1.18–2.17) and Pacific ethnicities (OR 1.88, 1.22–2.9, reference European). Conclusions We observed low adherence to STI retesting guidelines, and marked gender and ethnic disparities in rates of retesting and repeat positivity. Low retesting rates are suggestive of low levels of awareness of this aspect of patient management, and an absence of a systematic approach to retesting. High rates of repeat positivity reinforce the importance of advising patients about reducing their risk of reinfection, including notification and treatment of all recent sexual partners. Greater priority needs to be placed on increasing retesting and reducing rates of reinfection, with strategies implemented to improve these important aspects of patient care and population STI control.
机译:在最佳实践性健康管理指南中,建议对沙眼衣原体或淋病奈瑟氏球菌治疗后3到6个月进行重新感染的背景测试。这项研究旨在描述在新西兰特定地理区域诊断出衣原体或淋病后的复检率和重复阳性率。方法回顾性队列研究在新西兰惠灵顿进行,包括分析在初级保健和性健康诊所(2012年7月至2015年7月)进行的衣原体和淋病检测的实验室数据。结果指标:阳性结果后6周至6个月(指数事件)的复检率和重复阳性率。 Kaplan-Meier曲线用于绘制从第一个索引事件到重新测试的时间。使用逻辑回归模型确定随访6周和6月之间复测和重复阳性的几率,并针对潜在的混杂因素(年龄,性别,种族和社会经济剥夺)进行调整。结果整个队列的29.4%(1919/6530)在6周和6个月之间进行了重新测试,其中18%(347/1919)进行了重新测试。男性(OR 0.4,95%CI 0.34–0.48),新西兰毛利人(OR 0.72,0.61–0.85)和太平洋种族(OR 0.49,0.39–0.62,参考欧洲)的人发现重新测试的几率较低。与复检中重复阳性几率较高相关的因素包括男性(OR 2.0,1.14–2.82),年龄15–19岁(OR 1.78,1.32–2.41,参考20-24岁),衣原体/性腺感染(OR 2.39,1.32–4.35,仅衣原体参考),毛利人(OR 1.6,1.18–2.17)和太平洋种族(OR 1.88,1.22–2.9,参考欧洲)。结论我们观察到对STI重新检测指南的依从性较低,并且在重新检测率和重复阳性率方面存在明显的性别和种族差异。低复检率表明患者对这方面的治疗意识不足,并且缺乏系统的复检方法。较高的重复阳性率进一步加强了为患者提供减少再感染风险的建议的重要性,包括通知和治疗所有近期性伴侣。需要将更多的优先重点放在增加重新检测和降低再感染率上,并采取改善患者护理和人群性传播感染控制这些重要方面的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号